Alnylam Pharmaceuticals Financial Statements (ALNY)
|
|
|
|
Report date
|
|
|
10.02.2022 |
23.02.2023 |
15.02.2024 |
13.02.2025 |
12.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
844.3 |
1 037 |
1 828 |
2 248 |
3 714 |
|
4 287 |
|
Operating Income, bln rub |
|
|
-708.7 |
-785.1 |
-282.2 |
-176.9 |
501.6 |
|
752.1 |
|
EBITDA, bln rub |
? |
|
-661.6 |
-926.6 |
-258.2 |
-178.8 |
557.2 |
|
613.6 |
|
Net profit, bln rub |
? |
|
-852.8 |
-1 131 |
-440.2 |
-278.2 |
313.7 |
|
577.2 |
|
|
OCF, bln rub |
? |
|
-641.7 |
-541.3 |
104.2 |
-8.31 |
524.1 |
|
712.9 |
|
CAPEX, bln rub |
? |
|
76.4 |
72.1 |
62.2 |
34.3 |
58.7 |
|
71.6 |
|
FCF, bln rub |
? |
|
-718.1 |
-613.3 |
41.9 |
-42.6 |
465.4 |
|
641.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 413 |
1 654 |
1 800 |
2 102 |
2 535 |
|
2 716 |
|
Cost of production, bln rub |
|
|
140.1 |
168.8 |
310.4 |
323.4 |
677.2 |
|
819.0 |
|
R&D, bln rub |
|
|
792.2 |
883.0 |
1 004 |
1 126 |
1 324 |
|
1 420 |
|
Interest expenses, bln rub |
|
|
143.0 |
156.0 |
121.2 |
141.9 |
252.6 |
|
283.3 |
|
|
Assets, bln rub |
|
|
3 643 |
3 546 |
3 830 |
4 240 |
4 966 |
|
5 130 |
|
Net Assets, bln rub |
? |
|
588.2 |
-158.2 |
-220.6 |
67.1 |
789.2 |
|
1 075 |
|
Debt, bln rub |
|
|
997.6 |
1 320 |
1 305 |
2 743 |
1 278 |
|
1 273 |
|
Cash, bln rub |
|
|
2 436 |
2 192 |
2 439 |
2 695 |
2 908 |
|
3 009 |
|
Net debt, bln rub |
|
|
-1 438 |
-872.2 |
-1 134 |
48.9 |
-1 630 |
|
-1 736 |
|
|
Ordinary share price, rub |
|
|
169.6 |
237.7 |
191.4 |
235.3 |
397.7 |
|
287.0 |
|
Number of ordinary shares, mln |
|
|
118.5 |
121.7 |
124.9 |
127.7 |
131.0 |
|
132.9 |
|
|
Market cap, bln rub |
|
|
20 087 |
28 919 |
23 908 |
30 038 |
52 094 |
|
38 138 |
|
EV, bln rub |
? |
|
18 649 |
28 047 |
22 774 |
30 086 |
50 464 |
|
36 401 |
|
Book value, bln rub |
|
|
588 |
-158 |
-221 |
67 |
789 |
|
1 075 |
|
|
EPS, rub |
? |
|
-7.20 |
-9.30 |
-3.52 |
-2.18 |
2.39 |
|
4.34 |
|
FCF/share, rub |
|
|
-6.06 |
-5.04 |
0.34 |
-0.33 |
3.55 |
|
4.83 |
|
BV/share, rub |
|
|
4.97 |
-1.30 |
-1.77 |
0.53 |
6.02 |
|
8.09 |
|
|
EBITDA margin, % |
? |
|
-78.4% |
-89.3% |
-14.1% |
-7.95% |
15.0% |
|
14.3% |
|
Net margin, % |
? |
|
-101.0% |
-109.0% |
-24.1% |
-12.4% |
8.45% |
|
13.5% |
|
FCF yield, % |
? |
|
-3.57% |
-2.12% |
0.18% |
-0.14% |
0.89% |
|
1.68% |
|
ROE, % |
? |
|
-145.0% |
714.9% |
199.5% |
-414.6% |
39.8% |
|
53.7% |
|
ROA, % |
? |
|
-23.4% |
-31.9% |
-11.5% |
-6.56% |
6.32% |
|
11.3% |
|
|
P/E |
? |
|
-23.6 |
-25.6 |
-54.3 |
-108.0 |
166.0 |
|
66.1 |
|
P/FCF |
|
|
-28.0 |
-47.2 |
570.0 |
-705.3 |
111.9 |
|
59.5 |
|
P/S |
? |
|
23.8 |
27.9 |
13.1 |
13.4 |
14.0 |
|
8.90 |
|
P/BV |
? |
|
34.1 |
-182.8 |
-108.4 |
447.7 |
66.0 |
|
35.5 |
|
EV/EBITDA |
? |
|
-28.2 |
-30.3 |
-88.2 |
-168.2 |
90.6 |
|
59.3 |
|
Debt/EBITDA |
|
|
2.17 |
0.94 |
4.39 |
-0.27 |
-2.93 |
|
-2.83 |
|
|
R&D/CAPEX, % |
|
|
1 037% |
1 225% |
1 615% |
3 286% |
2 256% |
|
1 984% |
|
|
CAPEX/Revenue, % |
|
|
9.05% |
6.95% |
3.40% |
1.52% |
1.58% |
|
1.67% |
|
| Alnylam Pharmaceuticals shareholders |
